IMG-007 (OX40 Antagonist)
Phase 2bModerate-To-Severe Atopic Dermatitis
Data readoutStock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| IMG-007 (OX40 Antagonist) | Moderate-To-Severe Atopic Dermatitis | Phase 2b | Dec 31, 2027 | — |
Upcoming milestones
Moderate-To-Severe Atopic Dermatitis
Data readoutCompany profile
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.